Incentive policy evaluation on orphan drugs in the United States during 1983—2019YANG Jing-shu, YANG Dian-zheng, YANG Yue1921-1927
Analysis on the necessity of international multi-regional clinical trials of imported prophylactic vaccines in ChinaLI Ze-lin, YANG Jian-hong, DONG Jiang-ping1928-1933
Pharmacology and clinical evaluation of the RNA polymerase Ⅱ inhibitor lurbinectedinLAN Hua, ZHANG Ya-tong, WANG Yang1934-1939
Risankizumab: a new biological agent for the treatment of psoriasisLI Xiang-jun, WU Ai-ping, ZHANG Li1940-1943
Considerations on the application of antimicrobial preservatives in drugsTANG Zhen, ZHAO Xiao-xia, GUAN Hong-feng, ZHANG Yong-wen1944-1948
Discussion on the related problems of supplementary testing methods and items of traditional Chinese medicineCHEN Xia, ZHANG Yong-wen, ZHOU Gang1949-1955
General considerations for viral safety control of recombinant therapeutic biotechnological products during the CTA phaseSAI Wen-bo, GUO Sheng-nan, WEI Kai-kun1956-1960
The key issues in clinical research of investigational Chinese medicine in mammary hyperplasiaCHENG Jin-lian, ZHANG Dong-xiao, LIU Xue-mei1961-1966
Verification of applicability of the method for detecting CHO host cell protein residuesZHANG Feng, QIN Jian, GUO Sha, WANG Lan1967-1974
Preparation and preliminary characterization of anti-GPC3/NKG2D bispecific fusion proteinLIU Yun-hui, GE Chen, XU Qin-zhi, QIAN Ni-liang, YANG Hui, WAN Ling-fei, YAN Xin-long, GAO Xin1975-1981